Search company, investor...
Search
10X Genomics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

10xgenomics.com

Founded Year

2012

Stage

IPO | IPO

Total Raised

$277.04M

Date of IPO

9/12/2019

Market Cap

3.64B

Stock Price

30.23

About 10X Genomics

10X Genomics is a life science technology company building products to interrogate, understand and master biology. Its integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology.

10X Genomics Headquarters Location

6230 Stoneridge Mall Road

Pleasanton, California, 94588,

United States

925-401-7300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing 10X Genomics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned 10X Genomics in 5 CB Insights research briefs, most recently on Jul 6, 2022.

Expert Collections containing 10X Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

10X Genomics is included in 3 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

10X Genomics Patents

10X Genomics has filed 361 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/1/2020

9/13/2022

Polymers, Molecular biology, Dosage forms, Drug delivery devices, Polymer chemistry

Grant

Application Date

9/1/2020

Grant Date

9/13/2022

Title

Related Topics

Polymers, Molecular biology, Dosage forms, Drug delivery devices, Polymer chemistry

Status

Grant

Latest 10X Genomics News

10x Genomics : Statement of Changes in Beneficial Ownership - Form 4

Sep 16, 2022

09/16/2022 | 05:40pm EDT Message : FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL 1. Relationship of Reporting Person(s) to Issuer (Check all applicable) 3. Date of Earliest Transaction (Month/Day/Year) (Street) 6. Individual or Join/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) 1.Title of Security 3. Transaction Code 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership Code (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivate Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 4. Transaction Code 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative Security 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 11. Nature of Indirect Beneficial Ownership Code Reporting Owners 2022-09-16 (**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). (1) Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 25% of the RSUs vest on the one-year anniversary measured from August 21, 2022, and 1/16th of the RSUs vest quarterly thereafter, subject to the Reporting Person continuing as a service provider through each such date. (2) 25% of the shares subject to the option vest on the one-year anniversary measured from July 27, 2022, and 1/48th of the shares vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. Attachments

10X Genomics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

10X Genomics Rank

  • When was 10X Genomics founded?

    10X Genomics was founded in 2012.

  • Where is 10X Genomics's headquarters?

    10X Genomics's headquarters is located at 6230 Stoneridge Mall Road, Pleasanton.

  • What is 10X Genomics's latest funding round?

    10X Genomics's latest funding round is IPO.

  • How much did 10X Genomics raise?

    10X Genomics raised a total of $277.04M.

  • Who are the investors of 10X Genomics?

    Investors of 10X Genomics include Fidelity Investments, Meritech Capital Partners, Wells Fargo Strategic Capital, Paladin Capital Group, SoftBank Group and 8 more.

  • Who are 10X Genomics's competitors?

    Competitors of 10X Genomics include Singleron and 2 more.

You May Also Like

Analytical BioSciences Logo
Analytical BioSciences

Analytical BioSciences focuses on the research of single-cell genome research for human medicine, especially the establishment of single-cell big data platform, intelligent analysis process, and in-depth interpretation program.

S
SeekGene

SeekGene specializes in single-cell sequencing and TCR-pMHC pairing technologies in understanding immune responses in the single-cell resolution to help screen, treat and monitor diseases.

Singleron Logo
Singleron

Singleron is a developer of gene sequencing technology, focusing on massive and single-cell multi-omics analysis for drug development, scientific research, and genomics industries. The company develops a series of molecular diagnostic products and automation devices that can meet clinical applications.

Pacific Biosciences Logo
Pacific Biosciences

Pacific Biosciences of California (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its Single Molecule, Real-Time (SMRT) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.

Illumina Logo
Illumina

Illumina works to apply technologies and revolutionary assays to the analysis of genetic variation and function. It offers collaborative interactions, rapid delivery of solutions, and focuses on customers. Illumina's array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. The company was founded in 1998 and is based in San Diego, California.

Singular Genomics Logo
Singular Genomics

Singular Genomics (NASDAQ: OMIC) develops a third-gen DNA sequencing system. The sequencing by synthesis system is based on technology licensed out of Jingyue Ju's lab at Columbia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.